STEM CELLS Translational Medicine (SCTM) is dedicated to significantly advancing the clinical utilization of stem cell molecular and cellular biology. By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.
The potential of stem cells therapies and regenerative medicine is both provocative and powerful, offering the distinct possibility of eventually repairing or replacing tissues damaged from disease, including certain cancers. By helping speed expertly executed translations of emerging lab discoveries into legitimate clinical trials and bedside application, STEM CELLS Translational Medicine (SCTM) ultimately will improve patient outcomes.
STEM CELLS Translational Medicine ® (pISSN 2157-6564) STEM CELLS Translational Medicine Online (eISSN 2157-6580) are published 12 times per year by AlphaMed Press, 318 Blackwell Street, Suite 260, Durham, NC 27701-2884; 2 Henry Adams, Suite M35, San Francisco, CA 94103 USA; AlphaMed Europe, Ltd., Queen's University-Belfast, Centre for Cancer Research and Cell Biology, 97 Lisburn, Belfast, Northern Ireland, UK BT9 7BL.
While the publisher and Editorial Board make every effort to see that no inaccurate or misleading data, opinions, or statements appear in this journal, they wish to state that the data and opinions in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Accordingly, the publisher, Editorial Board, and their respective employees, officers, and agents accept no liability whatsoever for the consequences of any such inaccurate or misleading data, opinion or statement. While every effort is made to ensure drug doses and other quantities are presented accurately, readers are advised that new methods and techniques involving drug usage described within this journal should be followed only in conjunction with the drug manufacturer's own published literature.
Editorial correspondence, including submissions for publication or letters to the Editor, should be addressed to Editors@StemCellsTM.com.
Information for Contributors can be found here.
Advertising: Correspondence and rate requests should be addressed to the Publisher.
Change of Address notices: Both the subscriber's old and new address should be e-mailed to AlphaMed Press at least one month in advance. You can also mail the information to: AlphaMed Press, PO Box 412, Congers, New York 10920-9914 USA.